LIFECORE BIOMEDICAL, INC. Temporary Equity, Liquidation Preference
LIFECORE BIOMEDICAL, INC. (LFCR) had Temporary Equity, Liquidation Preference of $50.19 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Temporary Equity › Temporary Equity, Other Disclosure
us-gaap:TemporaryEquityLiquidationPreference · last filed 2026-08-05
- 2026-06-30: Temporary Equity, Liquidation Preference $50.19M.
- 2026-03-31: Temporary Equity, Liquidation Preference $49.26M.
- 2025-12-31: Temporary Equity, Liquidation Preference $48.36M.
- 2025-09-30: Temporary Equity, Liquidation Preference $47.47M.
| Period end | Temporary Equity, Liquidation Preference |
|---|---|
| 2026-06-30 | $50.19M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $49.26M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $48.36M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $47.47M 10-Q · filed 2025-11-06 |
| 2025-05-25 | $46.31M 10-KT · filed 2026-03-16 |
| 2025-02-23 | $45.45M 10-Q · filed 2025-04-03 |
| 2024-05-26 | $42.99M 10-KT · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |